Last update 21 Nov 2024

TIN816

Overview

Basic Info

Drug Type
Biological products
Synonyms
Target
ATP
Mechanism
ATP modulators(ATP modulators)
Therapeutic Areas
Infectious DiseasesUrogenital DiseasesOther Diseases
Active Indication
Acute Kidney InjuryAcute kidney injury due to sepsisSepsis
Inactive Indication-
Originator Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
Active Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.China Novartis Institutes for BioMedical Research Co., Ltd.Lonza AG
+ [1]
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with TIN816
CTR20240684 / RecruitingPhase 2
一项旨在评估单次静脉输注TIN816治疗脓毒症相关急性肾损伤（SA-AKI）受试者的安全性和疗效的多中心、随机、双盲、安慰剂对照、四臂、平行组、剂量探索IIb期研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding Phase IIb study to evaluate the safety and efficacy of a single intravenous infusion of TIN816 in subjects with sepsis-associated acute kidney injury (SA-AKI)
NCT05996835 / RecruitingPhase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (SA-AKI)
JPRN-jRCT2051230105 / RecruitingPhase 1IIT
A Phase 1, randomized, participant- and investigatorblinded, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of TIN816 in Japanese healthy participants
100 Clinical Results associated with TIN816
Login to view more data
100 Translational Medicine associated with TIN816
Login to view more data
100 Patents (Medical) associated with TIN816
Login to view more data
100 Deals associated with TIN816
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute kidney injury due to sepsisPhase 2
DE
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
Acute kidney injury due to sepsisPhase 2
ES
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
Acute kidney injury due to sepsisPhase 2
BE
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
Acute kidney injury due to sepsisPhase 2
FR
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
Acute kidney injury due to sepsisPhase 2
HU
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
SepsisPhase 2
HU
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
SepsisPhase 2
FR
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
SepsisPhase 2
ES
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
SepsisPhase 2
DE
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
SepsisPhase 2
BE
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
22 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free